



[Home](#) / [Investors](#) / [Press Releases](#)

Insmmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List

--*Insmmed Leads Science Top Employers List for Second Year in a Row*--

BRIDGEWATER, N.J., Oct. 27, 2022 /PRNewswire/ -- Insmmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has earned the highest ranking in *Science's* 2022 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.

"Receiving the top spot in *Science's* annual survey for two years in a row is a tremendous honor," said Will Lewis, Chair and Chief Executive Officer of Insmmed. "This recognition is a testament to the culture we have built, as well as the importance that we place on science and research. As we strive to achieve our ambitious goals for the future, I am grateful to our employees around the world for their passion, creativity, and dedication to patients."

The 2022 survey results were based on more than 6,200 responses from individuals across North America (63%), Europe (15%), Asia/Pacific Rim (17%), and other locations (5%). The highest-ranking companies on this year's list stood out in the areas of innovative leadership, respect for employees, and social responsibility. Following Insmmed, the top five companies this year included Alnylam, Regeneron, Incyte, and Syngenta Group.

"In today's hyper-competitive employment market, the demand for top talent is greater than ever," said Nicole Schaeffer, Chief People Strategy Officer of Insmmed. "I am proud that our continued focus on fostering a collaborative, inclusive, and values-driven culture sets us apart as a company where the brightest minds choose to spend their careers."

"It is an honor to work alongside our immensely talented Research team," said Eugene Sullivan, M.D., Chief Product Strategy Officer of Insmmed. "Today, we are pursuing some of the most innovative and cutting-edge technologies in the field of biopharmaceutical research, and I have never been more excited about where we are headed."

The complete feature and company rankings can be accessed [here](#). To learn more about Insmmed's culture and explore opportunities to join our team, please visit <https://insmed.com/culture/careers/>.

About Insmmed

Insmmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmmed
(732) 718-3621

amanda.fahey@insmed.com

SOURCE Insmmed Incorporated
